HIV Glasgow 23-26 October 2016

Conference Reports for NATAP


HIV Glasgow 23-26 October 2016 Glasgow, UK

	HIV+ Aging, Comorbidites & Mortality in Belgium - (09/26/17) Frailty in HIV+ in Italy....average age only 49 but 12% frail, 28% pre-frail, 33% some measure of depression, 51% cognitive impairment. - (09/26/17) Use of dolutegravir in combination with rifampicin based TB therapy in HIV/TB co-infected patients - (09/26/17) Utilizing Phase 3 Clinical Trial Data to Assess Adverse Event (AE) Frequency of a Potentially Interacting Medication (PIM) Amlodipine with Elvitegravir/Cobicistat (EVG/COBI) - (04/04/17) Psychiatric Symptoms in Patients Receiving Dolutegravir - (01/25/17) Adverse Events and Discontinuation of Dolutegravir based therapy in naïve and experienced HIV patients: tertiary HIV center experience - (01/25/17) Neurologic Involvement in patients with Acute/Recent HIV Infection - (12/22/16) Hepatic Steatosis is Highly Prevalent in HIV and Significantly Associated with Diabetes Risk - (12/15/16) Switch to dolutegravir in HIV patients responding to a first line antiretroviral treatment- 48 weeks results - (12/02/16) Non-inferiority of dual-therapy with darunavir/ritonavir plus 3TC vs. triple therapy with darunavir/ritonavir plus TDF/FTC or ABC/3TC for maintenance of viral suppression: 48-week results of the DUAL-GESIDA 8014-RIS-EST45 Trial - DUAL: "DarUnavir And Lamivudine" - (11/09/16) Changes in the Prevalence of Cardiovascular, Renal and Bone Co-Morbidities and Related Risk Factor in HIV-Infected Patients in The Spanish VACH Cohort: A Cross-Sectional Study in 2010 and 2014.... - (11/09/16) Helping the HIV Physician through the challenges of co-morbidities in decision making - (11/09/16) Discontinuation of Dolutegravir (DTG)-based Regimens in Clinical Practice - (11/09/16) Cognitive function and depression in HIV-positive individuals and matched controls - (11/08/16) Aging in France Report - (11/08/16) HEALTH-RELATED COSTS IN CHRONIC HIV INFECTION: A CASE-CONTROL STUDY VS. GENERAL POPULATION USING A CLAIMS-BASED APPROACH IN GERMANY....healthcare/drug costs soar for HIV+ aging compared to HIV-neg. - (11/08/16) COMORBITY IN CHRONIC HIV INFECTION A CASE-CONTROL STUDY IN GERMANY USING HEALTH INSURANCE CLAIMS DATA [Examines 70-80+ Year Olds. Higher Prevalence of Comorbidities in HIV+ vs HIV-neg] - (11/08/16) Antiretroviral Treatment Patterns in the US: An Analysis of Real World Data - (11/08/16) First-Line Antiretroviral Treatment Characteristics Among HIV-Infected Patients With and Without Comorbidities.....High Comorbidities Rates in 40 Year Old (SD-12) HIV+....." - (11/08/16) Mortality rates and excess mortality among HIV-positive persons according to age in Spain, 2004-2014 - (11/08/16) Discontinuation of Dolutegravir (DTG)-based Regimens in Clinical Practice - (11/08/16) HIV PATIENTS TODAY AND 10 YEARS AGO: DO THEY HAVE THE SAME NEEDS? RESULTS FROM CROSS SECTIONAL ANALYSIS OF ANRS CO3 AQUITAINE COHORT - (11/05/16) Uncontrolled HIV Tied to NHL But Not Hodgkins in Large D:A:D Study - Differences in virological and immunological risk factors for non-Hodgkin and Hodgkin lymphoma: The D:A:D study - Mark Mascolini - (11/05/16) Outcomes of Cabotegravir (CAB) Treatment in HIV-1 ART-Naive Patients With Chronic or Acute Hepatitis C Virus (HCV) Co-infection: Data From the Phase IIbProgramme - (11/02/16) Quantifying the future clinical burden of an ageing HIV-positive population in Italy: a mathematical modelling study - (11/02/16) Quantifying the future clinical burden of an ageing HIV-positive population in the USA:a mathematical modelling study - (11/02/16) Efficacy and safety of long acting HIV fusion inhibitor albuvirtide in antiretroviral-experienced adults with HIV-1: interim 48 week results from the randomized, controlled, phase 3, non-inferiority TALENT study - (11/02/16) Tryptophan Metabolism and its Relationship with Central Nervous System Toxicity in Subjects Switching from Efavirenz to Dolutegravir - (11/02/16) Baseline characteristics of the TRIUMPH and DOL-ART cohorts: Use of Triumeq® (DTG/ABC/3TC) or other DTG-based ART in routine clinical care in Germany - Comorbidities/Polypharmacy - (11/02/16) The DOL-ART Cohort: providing evidence from real world data -Use of Dolutegravir-based regimens in routine clinical care in Germany - (11/02/16) Changes in the Prevalence of Cardiovascular, Renal and Bone Co-Morbidities and Related Risk Factor in HIV-Infected Patients in The Spanish VACH Cohort: A Cross-Sectional Study in 2010 and 2014.... - (11/02/16) HIV-1 Attachment Inhibitor Prodrug BMS-663068 [GSK3684934 (formerly BMS-663068)] in Antiretroviral-Experienced Subjects: Week 96 Safety Analysis - (11/02/16) Safety and efficacy of dolutegravir plus rilpivirine (DTG/RPV) in treatment-experienced HiV-infected patients: preliminary results at 24 weeks of the DORiViR study - (10/31/16) Switch to E/C/F/TAF + DRV Superior to No Switch Despite High Resistance - Resistance Profile Analysis of Treatment-Experienced HIV-1 Infected Patients Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) plus Darunavir (DRV) - Mark Mascolini - (10/30/16) HIV-1 Attachment Inhibitor Prodrug BMS-663068 [GSK3684934 (formerly BMS-663068)] in Antiretroviral-Experienced Subjects: Week 96 Subgroup Analysis - (10/30/16) HIV Combinectin GSK3732394: A Long-Acting Inhibitor With Multiple Modes of Action - (10/30/16) Changes in the Prevalence of Cardiovascular, Renal and Bone Co-Morbidities and Related Risk Factor in HIV-Infected Patients in The Spanish VACH Cohort: A Cross-Sectional Study in 2010 and 2014.... - (10/30/16) Smoking, Nadir CD4s, and PI Use Tied to Bone Quality in Irish Group - The relative impact of antiretroviral drugs and baseline immune status on bone quality in HIV-positive subjects: results from the HIV UPBEAT cohort - Mark Mascolini - (10/27/16) Changes in kidney function in patients with suppressed HIV RNA who substitute their protease inhibitor with atazanavir/ritonavir - (10/27/16) Improved kidney function in patients who switch their protease inhibitor from atazanaviror lopinavir to darunavir - (10/27/16) Kidney Function Improves After Switch From LPV or ATV to DRV - Mark Mascolini (10/27/16) Kidney Function Improves After Switch From LPV or ATV to DRV - (10/27/16) Third ARV Does Not Affect Safety Gains in Switch From TDF/FTC to TAF/FTC - Efficacy and Safety of Emtricitabine/Tenofovir Alafenamide vs Emtricitabine/Tenofovir Disoproxil Fumarate as a Backbone for Treatment of HIV-1 Infection in Virologically Suppressed Adults: Subgroup Analysis by 3rd Agent - (10/27/16) - Mark Mascolini Sofosbuvir/Velpatasvir Single Tablet Regimen in HCV Monoinfected and HIV/HCV Coinfected Patients: Comparison of Efficacy and Safety Data from Phase 3 Clinical Trials - (10/26/16) Lower Long-Term Risk or Death or AIDS With Lipoatrophy or Lipodystrophy - (10/26/16) Lower Long-Term Risk or Death or AIDS With Lipoatrophy or Lipodystrophy - (10/26/16) HIV DNA Vanishes ["Cure"?] After CCR5-delta32 Stem Cell Transplant, But ART Continues - Mark Mascolini (10/26/16) Subgroup Analyses from ONCEMRK, a Phase 3 Study of Raltegravir (RAL) 1200 mg Once Daily vs RAL 400 mg Twice Daily, in Combination with Tenofovir/Emtricitabine, in Treatment-Naïve HIV-1 Infected Subjects - (10/26/16) Efficacy of Dolutegravir/Abacavir/Lamivudine Fixed-Dose Combination Compared With Ritonavir-Boosted Atazanavir Plus Tenofovir Disoproxil Fumarate/Emtricitabine in Treatment-Naive Women With HIV-1 Infection (ARIA Study): Subgroup Analyses - (10/26/16) Psychiatric Adverse Events From the DTG ART-Naive Phase III/IIIb Clinical Trials - (10/26/16) Switching from cART to dolutegravir monotherapy in virologically suppressed HIV-1 infected patients: A randomized clinical trial (DOMONO) - poster - (10/26/16) Efficacy and Safety of Emtricitabine/Tenofovir Alafenamide vs Emtricitabine/Tenofovir Disoproxil Fumarate as a Backbone for Treatment of HIV-1 Infection in Virologically Suppressed Adults: Subgroup Analysis by 3rd Agent - (10/25/16) 48 Week Results from two studies: Switching to RPV/FTC/TAF from EFV/FTC/TDF (Study 1160) or RPV/FTC/TDF (Study 1216) - (10/25/16) Higher Rates of Neuropsychiatric Adverse Events Leading to Dolutegravir Discontinuation in Women and Older Patients - (10/25/16) Proportion of US HIV Patients With 3 or More Comorbidities Will Rise 4-Fold by 2035 - Mark Mascolini - (10/25/16) Future challenges for clinical care of an ageing population infected with HIV: a ''geriatric HIV'' modeling study...... - (10/25/16) Prevalence of All Comorbidities Up From 2004 to 2014 in Big French Cohort - Mark Mascolini - (10/25/16) Switch to E/C/F/TAF + DRV Superior to No Switch Despite High Resistance - Mark Mascolini - (10/25/16) Safety and efficacy of dolutegravir plus rilpivirine (DTG/RPV) in treatment-experienced HIV-infected patients: preliminary results at 24 weeks of the DORIVIR study - Mark Mascolini - (10/25/16) Rates of All Age-Related Comorbidities Rise in EuroSIDA From 2006 to 2014 - (10/25/16) Gilead Presents Results from Phase 3 Studies Evaluating Switching to Descovy® (FTC/TAF)-Based Regimens from Truvada® (FTC/TDF)-Based Regimens - (10/24/16) Durability and tolerability of first-line combination including two NRTI and RAL or ATV/r or DRV/r in patients enrolled in the ICONA Foundation Cohort - (10/24/16)